Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Adempas (riociguat by Year
Adempas (riociguat — direct Merck territory sales) — U.S. sales ($M) ($M)
Merck Adempas (riociguat: $0M in FY2025. That is the highest of the 10 years on record here.
Latest, FY2025
0
Period ended Dec 31, 2025
Change on a year earlier
–
0 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adempas (riociguat — direct Merck territory sales) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Adempas (riociguat ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-direct-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.